FDA committee votes to pull boxed warning from Chantix
Pfizer has moved a giant leap closer to getting the strongest warning of serious neuropsychiatric events removed from the labelling of its anti-smoking drug Chantix in the US.
Read More
Tag: Champix
EU lifts neuropsychiatric warning for Pfizer’s Champix
European regulators have removed the black triangle warning from the label of Pfizer’s smoking cessation drug Champix, on the back of data from a post-marketing surveillance study backing its neuropsychiatric safety.
Read More
- European life sciences coalition launched to boost investment ecosystem
- 99mtc‑maraciclatide granted fast track status for ILD imaging
- Bioxytran reports rapid viral clearance in phase 2 trial
- Thx Pharma and Biocodex sign rare disease licensing deal
- AstraZeneca bladder cancer therapy wins NICE backing
